Emergent BioSolutions Inc. (EBS)
| Market Cap | 481.16M |
| Revenue (ttm) | 1.13B |
| Net Income (ttm) | -208.80M |
| Shares Out | 54.18M |
| EPS (ttm) | -3.98 |
| PE Ratio | n/a |
| Forward PE | 3.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,063,733 |
| Open | 8.21 |
| Previous Close | 8.27 |
| Day's Range | 8.12 - 8.97 |
| 52-Week Range | 1.42 - 15.10 |
| Beta | 1.57 |
| Analysts | Buy |
| Price Target | 14.00 (+57.66%) |
| Earnings Date | Nov 6, 2024 |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d... [Read more]
Full Company ProfileFinancial Performance
In 2023, Emergent BioSolutions's revenue was $1.05 billion, a decrease of -6.10% compared to the previous year's $1.12 billion. Losses were -$760.50 million, 259.4% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $14.0, which is an increase of 57.66% from the latest price.
News
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence po...
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
On Thursday, Emergent BioSolutions Inc. EBS stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.
Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and ...
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasa...
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2,...
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment co...
Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines
On Wednesday, Emergent BioSolutions Inc. EBS said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and mpox product portfolio.
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 $185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical Ad...
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company New favorable terms position Emergent for sus...
Upside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk opportunities in pharma investing following approval of Emergent Bio's Mpox vaccine.
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
GAITHERSBURG, Md., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced it is kicking off the second year of the Ready to Rescue initiative, which will include ne...
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
Thursday, the FDA approved Emergent BioSolutions Inc.'s EBS supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Li...
Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine
The FDA approves the company's smallpox vaccine for Mpox.
US FDA approves use of Emergent's smallpox vaccine for people at high risk of mpox
Emergent BioSolutions on Thursday said the U.S. Food and Drug Administration (FDA) had approved expanded use of its ACAM2000 smallpox vaccine to include people at high risk for mpox infection.
Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics Lic...
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate o...
Emergent to donate 50,000 vaccine doses to address mpox outbreak in Africa
Emergent BioSolutions said on Monday it would donate 50,000 doses of its vaccine, ACAM2000, to the Democratic Republic of the Congo and other impacted countries of Burundi, Kenya, Rwanda and Uganda to...
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
GAITHERSBURG, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it is proactively working with the World Health Organization (WHO) and the U.S. government to par...
Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
Emergent BioSolutions is a key player in public health. Its flagship product, NARCAN, is central to combating the opioid crisis. EBS stock rally is likely driven by its smallpox vaccine, ACAM2000, whi...
Health stocks jump as WHO declares mpox global health emergency
Shares of Danish vaccine maker Bavarian Nordic jumped as much as 17% Thursday amid a wider rally for associated healthcare stocks. It comes after the World Health Organization declared an escalating m...
Mpox outbreak: 5 stocks to watch out for as the emergency unfolds
The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to sprea...
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
On Tuesday, Emergent BioSolutions Inc. EBS reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million.